These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 1087182)

  • 1. Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model.
    Sirotnak FM; Donsbach RC; Moccio DM; Dorick DM
    Cancer Res; 1976 Dec; 36(12):4679-86. PubMed ID: 1087182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models.
    Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
    Cancer Res; 1976 Dec; 36(12):4672-8. PubMed ID: 1000510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
    Sirotnak FM; Moccio DM; Dorick DM
    Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells.
    Whitehead VM
    Cancer Res; 1977 Feb; 37(2):408-12. PubMed ID: 832265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of folate analogue transport inward in L1210 cells during methotrexate therapy of leukemic mice: evidence of the nature of the effect, possible host mediation, and pharmacokinetic significance.
    Sirotnak FM; Poser RE; Barrueco JR
    Cancer Res; 1987 Oct; 47(20):5334-9. PubMed ID: 3498533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors.
    Sirotnak FM; Donsback RC
    Cancer Res; 1975 Jul; 35(7):1737-44. PubMed ID: 1169115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of reduced folate changes to inhibition of DNA synthesis induced by methotrexate in L1210 cells in vivo.
    Priest DG; Bunni M; Sirotnak FM
    Cancer Res; 1989 Aug; 49(15):4204-9. PubMed ID: 2743307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose methotrexate therapy with citrovorum factor: a pharmacologic perspective in murine tumor models.
    Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
    Cancer Treat Rep; 1977 Jul; 61(4):565-74. PubMed ID: 301778
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo.
    Poser RG; Sirotnak FM; Chello PL
    Cancer Res; 1981 Nov; 41(11 Pt 1):4441-6. PubMed ID: 6171339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic basis for differences in methotrexate sensitivity of normal proliferative tissues in the mouse.
    Sirotnak FM; Moccio DM
    Cancer Res; 1980 Apr; 40(4):1230-4. PubMed ID: 7357552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.
    Matherly LH; Barlowe CK; Goldman ID
    Cancer Res; 1986 Feb; 46(2):588-93. PubMed ID: 2416428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
    Samuels LL; Straw JA
    Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues.
    Chabner BA; Young RC
    J Clin Invest; 1973 Aug; 52(8):1804-11. PubMed ID: 4719662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and selective effects of 1-beta-D-arabinofuranosylcytosine in L1210 and Host tissues in vivo.
    Chou TC; Hutchinson DJ; Schmid FA; Philips FS
    Cancer Res; 1975 Jan; 35(1):225-36. PubMed ID: 1109791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine L1210 leukemia.
    Klubes P; Cerna I
    Cancer Treat Rep; 1981; 65(1-2):107-14. PubMed ID: 7226161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative biochemical aspects of low and high doses of methotrexate in mice.
    Zaharko DS; Fung WP; Yang KH
    Cancer Res; 1977 Jun; 37(6):1602-7. PubMed ID: 870175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
    Sirotnak FM; Otter GM; Schmid FA
    Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of methotrexate on the leukemic cell cycle in mouse ascitic leukemia L1210].
    Goncharova SA; Frankfurt OS
    Tsitologiia; 1975 Sep; 17(9):1051-6. PubMed ID: 1166521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of high-dose methotrexate and leucovorin on murine hemopoietic stem cells.
    Pannacciulli I; Massa G; Bogliolo G; Ghio R; Sobrero A
    Cancer Res; 1982 Feb; 42(2):530-4. PubMed ID: 6976827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.
    Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID
    Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.